PRKCQ Knockout A549 Cell Pool

热销产品

undefined
undefined
+
  • undefined
  • undefined

编号 :

LM01100065675

产品编号: LM01100065675

市场价

销售价格:  ¥ 8499

数量
-
+

库存剩余

联系我们订购

抗体定制服务咨询

隐藏域元素占位

  • 产品描述
  • 细胞复苏
  • 细胞传代
  • 细胞冻存
  • 抗体验证结果
    • 品牌: ELEMok138cn太阳集团529
    • 商品名称: PRKCQ Knockout A549 Cell Pool
    • 商品编号: LM01100065675
    • Gene Symbol: PRKCQ
    • Ensembl ID: ENSG00000065675
    • Uniprot ID: Q04759
    • 宿主细胞 / 类型: A549/人非小细胞肺癌细胞
    • NCBI Gene ID: 5588
    • 规格: 1×10^6 cells/ 冻存管
    • 筛选标记: N/A
    • 生长特性: 贴壁细胞,上皮细胞样
    • 培养条件: 37℃,5% CO2 的培养箱,1/2 到 1/3 传代
    • 倍增时间: ~22 hours
    • 生长培养基: MEM+10%FBS+100U/ml Penicillin-Strep
    • 参考换液频率: 2-3天换液
    • 支原体检测结果: 阴性
    • 敲除效率(Sanger测序): 95%
    • 蛋白质组验证结果: 已完成蛋白水平验证
    • 抗体货号: 添加中
    • 目标基因介绍: Calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that mediates non-redundant functions in T-cell receptor (TCR) signaling, including T-cells activation, proliferation, differentiation and survival, by mediating activation of multiple transcription factors such as NF-kappa-B, JUN, NFATC1 and NFATC2. In TCR-CD3/CD28-co-stimulated T-cells, is required for the activation of NF-kappa-B and JUN, which in turn are essential for IL2 production, and participates in the calcium-dependent NFATC1 and NFATC2 transactivation. Mediates the activation of the canonical NF-kappa-B pathway (NFKB1) by direct phosphorylation of CARD11 on several serine residues, inducing CARD11 association with lipid rafts and recruitment of the BCL10-MALT1 complex, which then activates IKK complex, resulting in nuclear translocation and activation of NFKB1. May also play an indirect role in activation of the non-canonical NF-kappa-B (NFKB2) pathway. In the signaling pathway leading to JUN activation, acts by phosphorylating the mediator STK39/SPAK and may not act through MAP kinases signaling. Plays a critical role in TCR/CD28-induced NFATC1 and NFATC2 transactivation by participating in the regulation of reduced inositol 1,4,5-trisphosphate generation and intracellular calcium mobilization. After costimulation of T-cells through CD28 can phosphorylate CBLB and is required for the ubiquitination and subsequent degradation of CBLB, which is a prerequisite for the activation of TCR. During T-cells differentiation, plays an important role in the development of T-helper 2 (Th2) cells following immune and inflammatory responses, and, in the development of inflammatory autoimmune diseases, is necessary for the activation of IL17-producing Th17 cells. May play a minor role in Th1 response. Upon TCR stimulation, mediates T-cell protective survival signal by phosphorylating BAD, thus protecting T-cells from BAD-induced apoptosis, and by up-regulating BCL-X(L)/BCL2L1 levels through NF-kappa-B and JUN pathways. In platelets, regulates signal transduction downstream of the ITGA2B, CD36/GP4, F2R/PAR1 and F2RL3/PAR4 receptors, playing a positive role in 'outside-in' signaling and granule secretion signal transduction. May relay signals from the activated ITGA2B receptor by regulating the uncoupling of WASP and WIPF1, thereby permitting the regulation of actin filament nucleation and branching activity of the Arp2/3 complex. May mediate inhibitory effects of free fatty acids on insulin signaling by phosphorylating IRS1, which in turn blocks IRS1 tyrosine phosphorylation and downstream activation of the PI3K/AKT pathway. Phosphorylates MSN (moesin) in the presence of phosphatidylglycerol or phosphatidylinositol. Phosphorylates PDPK1 at 'Ser-504' and 'Ser-532' and negatively regulates its ability to phosphorylate PKB/AKT1. Phosphorylates CCDC88A/GIV and inhibits its guanine nucleotide exchange factor activity (PubMed:23509302).
    • 细胞开发路径: 采用CRISPR-RNP方法生成稳定KO Cell Pool;Sanger 测序结果显示KO Cell Pool敲除效率95%
    • 应用: 高敲除效率的基因敲除细胞池(KO Cell Pool),特别适用于初步功能分析、复杂疾病模型的开发、精准药物筛选以及广泛的基因发现研究。KO pool能够无需繁琐的单克隆挑选过程,直接应用于多种类型的测定和分析,大幅提升实验效率。
    关键词:
    • PRKCQ
  • 01.  在 37℃水浴中预热完全培养基。
    02.  将冻存管在 37℃水浴中解冻 1-2 分钟。
    03.  将冻存管转移到生物安全柜中,并用 70% 乙醇擦拭表面。
    04.  拧开冻存管管盖,将细胞悬液轻轻转移到含有 9mL 完全培养基的无菌离心管中。
    05.  在室温下以 125g 离心 5-7 分钟,弃上清。
    06.  用 5mL 的完整培养基重悬细胞沉淀,将细胞悬液转移到 T25 培养瓶中。
    07.  将细胞转移到 37℃,5% CO2 的培养箱中培养。
    08.  参考传代比例:1/2 到 1/3 传代,2-3 天长满。

  • 01.  待培养瓶中细胞汇合度至 80%-90% 以上,可进行细胞传代。
    02.  将培养基、PBS、胰酶(0.25%Trypsin_EDTA Gibco 25200-056) 等从 4℃冰箱中拿出, 置于 37℃水浴中温度接近 37℃时取出并在瓶子表面喷洒 75% 酒精后置于生物安全柜中。

    03.  从培养箱中取出待传代的培养瓶,瓶身喷洒 75% 酒精后置于生物安全柜中。
    04.  为避免冲散细胞,沿培养瓶上壁 PBS 润洗细胞,清洗细胞后弃去,T25 加 2mL。
    05.  加入对应体积的胰酶(T75 加 1.5mL, T25 加 0.5mL)  ,并轻轻晃动瓶身使胰酶平铺满细胞 底部。可根据实际情况适当增加或减少用量。约 1-2min 后大部分细胞脱落时,加入对应体积的完全培养基终止消化,并用 5mL 移液管轻轻吹打至细胞全部脱落。
    06.  将细胞悬液转移至 15mL 离心管,悬液 300g 离心 5min,弃上清。
    07.  移取 5mL 完全培养基重悬细胞,按需求调整接种比例,并补充培养瓶中完全培养基,T75 加至 13-15mL,T25 加至 5mL,加 1% 双抗。
    08.  盖上瓶盖拧紧后轻轻晃动瓶身,使细胞混合均匀后置于 37℃,5% CO2 培养箱中。

  • 01.  准备冻存液,并提前预冷。
    02.  确保待冻存的细胞满足冻存要求,用显微镜检查以下状态:健康的外观及形态特征、所处生 长周期(对数晚期)、无污染或衰退迹象。
    03.  对细胞进行消化及离心处理(具体步骤参考传代培养流程)
    04.  按照每管 1mL 的量添加冻存液重悬细胞,吹打均匀后分装至冻存管。
    05.  将细胞放在程序降温盒中,在 -80℃冰箱中冷冻。
    06.  后续将细胞转移到液氮罐中,以便长期储存。

  • 抗体验证中

产品类型: 基因敲除细胞池(蛋白水平已验证)

细胞系信息

Gene Symbol

PRKCQ

NCBI Gene ID

5588

Ensembl ID

ENSG00000065675

Uniprot ID

Q04759

筛选标记

N/A

宿主细胞 / 类型

A549/人非小细胞肺癌细胞

规格

1×10^6 cells/ 冻存管

生长培养基

MEM+10%FBS+100U/ml Penicillin-Strep

生长特性

贴壁细胞,上皮细胞样

培养条件

37℃,5% CO2 的培养箱,1/2 到 1/3 传代

倍增时间

~22 hours

参考换液频率

2-3天换液

支原体检测结果

阴性

敲除验证

敲除效率(Sanger测序)

95%

蛋白质组验证结果

已完成蛋白水平验证

抗体货号

添加中

抗体验证结果

抗体验证中

细胞系说明

目标基因介绍

Calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that mediates non-redundant functions in T-cell receptor (TCR) signaling, including T-cells activation, proliferation, differentiation and survival, by mediating activation of multiple transcription factors such as NF-kappa-B, JUN, NFATC1 and NFATC2. In TCR-CD3/CD28-co-stimulated T-cells, is required for the activation of NF-kappa-B and JUN, which in turn are essential for IL2 production, and participates in the calcium-dependent NFATC1 and NFATC2 transactivation. Mediates the activation of the canonical NF-kappa-B pathway (NFKB1) by direct phosphorylation of CARD11 on several serine residues, inducing CARD11 association with lipid rafts and recruitment of the BCL10-MALT1 complex, which then activates IKK complex, resulting in nuclear translocation and activation of NFKB1. May also play an indirect role in activation of the non-canonical NF-kappa-B (NFKB2) pathway. In the signaling pathway leading to JUN activation, acts by phosphorylating the mediator STK39/SPAK and may not act through MAP kinases signaling. Plays a critical role in TCR/CD28-induced NFATC1 and NFATC2 transactivation by participating in the regulation of reduced inositol 1,4,5-trisphosphate generation and intracellular calcium mobilization. After costimulation of T-cells through CD28 can phosphorylate CBLB and is required for the ubiquitination and subsequent degradation of CBLB, which is a prerequisite for the activation of TCR. During T-cells differentiation, plays an important role in the development of T-helper 2 (Th2) cells following immune and inflammatory responses, and, in the development of inflammatory autoimmune diseases, is necessary for the activation of IL17-producing Th17 cells. May play a minor role in Th1 response. Upon TCR stimulation, mediates T-cell protective survival signal by phosphorylating BAD, thus protecting T-cells from BAD-induced apoptosis, and by up-regulating BCL-X(L)/BCL2L1 levels through NF-kappa-B and JUN pathways. In platelets, regulates signal transduction downstream of the ITGA2B, CD36/GP4, F2R/PAR1 and F2RL3/PAR4 receptors, playing a positive role in 'outside-in' signaling and granule secretion signal transduction. May relay signals from the activated ITGA2B receptor by regulating the uncoupling of WASP and WIPF1, thereby permitting the regulation of actin filament nucleation and branching activity of the Arp2/3 complex. May mediate inhibitory effects of free fatty acids on insulin signaling by phosphorylating IRS1, which in turn blocks IRS1 tyrosine phosphorylation and downstream activation of the PI3K/AKT pathway. Phosphorylates MSN (moesin) in the presence of phosphatidylglycerol or phosphatidylinositol. Phosphorylates PDPK1 at 'Ser-504' and 'Ser-532' and negatively regulates its ability to phosphorylate PKB/AKT1. Phosphorylates CCDC88A/GIV and inhibits its guanine nucleotide exchange factor activity (PubMed:23509302).

细胞开发路径

采用CRISPR-RNP方法生成稳定KO Cell Pool;Sanger 测序结果显示KO Cell Pool敲除效率95%

应用

高敲除效率的基因敲除细胞池(KO Cell Pool),特别适用于初步功能分析、复杂疾病模型的开发、精准药物筛选以及广泛的基因发现研究。KO pool能够无需繁琐的单克隆挑选过程,直接应用于多种类型的测定和分析,大幅提升实验效率。

细胞培养说明

细胞复苏

01.  在 37℃水浴中预热完全培养基。
02.  将冻存管在 37℃水浴中解冻 1-2 分钟。
03.  将冻存管转移到生物安全柜中,并用 70% 乙醇擦拭表面。
04.  拧开冻存管管盖,将细胞悬液轻轻转移到含有 9mL 完全培养基的无菌离心管中。
05.  在室温下以 125g 离心 5-7 分钟,弃上清。
06.  用 5mL 的完整培养基重悬细胞沉淀,将细胞悬液转移到 T25 培养瓶中。
07.  将细胞转移到 37℃,5% CO2 的培养箱中培养。
08.  参考传代比例:1/2 到 1/3 传代,2-3 天长满。

细胞传代

01.  待培养瓶中细胞汇合度至 80%-90% 以上,可进行细胞传代。
02.  将培养基、PBS、胰酶(0.25%Trypsin_EDTA Gibco 25200-056) 等从 4℃冰箱中拿出, 置于 37℃水浴中温度接近 37℃时取出并在瓶子表面喷洒 75% 酒精后置于生物安全柜中。

03.  从培养箱中取出待传代的培养瓶,瓶身喷洒 75% 酒精后置于生物安全柜中。
04.  为避免冲散细胞,沿培养瓶上壁 PBS 润洗细胞,清洗细胞后弃去,T25 加 2mL。
05.  加入对应体积的胰酶(T75 加 1.5mL, T25 加 0.5mL)  ,并轻轻晃动瓶身使胰酶平铺满细胞 底部。可根据实际情况适当增加或减少用量。约 1-2min 后大部分细胞脱落时,加入对应体积的完全培养基终止消化,并用 5mL 移液管轻轻吹打至细胞全部脱落。
06.  将细胞悬液转移至 15mL 离心管,悬液 300g 离心 5min,弃上清。
07.  移取 5mL 完全培养基重悬细胞,按需求调整接种比例,并补充培养瓶中完全培养基,T75 加至 13-15mL,T25 加至 5mL,加 1% 双抗。
08.  盖上瓶盖拧紧后轻轻晃动瓶身,使细胞混合均匀后置于 37℃,5% CO2 培养箱中。

细胞冻存

01.  准备冻存液,并提前预冷。
02.  确保待冻存的细胞满足冻存要求,用显微镜检查以下状态:健康的外观及形态特征、所处生 长周期(对数晚期)、无污染或衰退迹象。
03.  对细胞进行消化及离心处理(具体步骤参考传代培养流程)
04.  按照每管 1mL 的量添加冻存液重悬细胞,吹打均匀后分装至冻存管。
05.  将细胞放在程序降温盒中,在 -80℃冰箱中冷冻。
06.  后续将细胞转移到液氮罐中,以便长期储存。

XML 地图